Zimulti
Zimulti (rimonabant) is the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1). Zimulti is used in the treatment of obesity and related conditions.
Consumer Information (Drugs.com) · More like this · Add to my drug list

Acomplia Information from Drugs.com
Acomplia is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in...
Consumer Information (Drugs.com) · More like this · Add to my drug list

Sanofi-aventis First Half 2007: Solid Results in a Difficult Context;
...States, which has confirmed the validity and enforceability of U.S. patent covering the active ingredient until November 2011 Withdrawal of the Zimulti(R) application in the United States following a negative recommendation from the Advisory Committee of the FDA. Sanofi-aventis remains committed...
News & Articles (Drugs.com) · More like this

Committee for Medicinal Products for Human Use Post-authorisation Summary of Positive Opinion for Acomplia/Zimulti
...Use (CHMP) adopted a positive opinion** to recommend the variation to the terms of the marketing authorisation for the medicinal products Acomplia/Zimulti. The Marketing Authorisation Holder for these medicinal products is sanofi-aventis. The CHMP adopted a new contraindication as follows: 'Ongoing...
New Drug Applications (FDA) · More like this

FDA Advisory Committee Did Not Recommend Approval of Rimonabant (Zimulti) for Use in Obese and Overweight Patients With Associated Risks Factors
...that the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee did not recommend approval of rimonabant (Zimulti) to the US FDA for use in obese and overweight patients with associated risks factors. Sanofi-aventis will continue to work closely with the FDA...
New Drug Applications (FDA) · More like this